BioAlliance Pharma extends and strengthens the protection of AMEP® with the grant of two patents in the US
13 July 2012 - 2:18AM
Business Wire
Regulatory News:
BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an
innovative Company dedicated to the development of orphan oncology
products and to supportive care products, announces two key
achievements in the development of its biotherapy AMEP® with the
decision of granting two patents by the USPTO (United States Patent
and Trademark Office).
AMEP® is a protein targeting specific receptors expressed on
melanoma cells and involved in both tumor growth and angiogenesis
(inhibition of tumor vascularization necessary for its growth). As
the protein cannot be directly administered, the Company has
developed a technology aiming at administering the specific gene
(the AMEP® biotherapy) which, once inside the cell, will enable
synthesis of the active AMEP® protein.
After Asia and Europe, BioAlliance Pharma has obtained the US
patent protecting the metastatic melanoma treatment by the AMEP®
biotherapy. This patent provides a protection until 2022. Moreover,
the USPTO has recently given its allowance to deliver another
patent on this same product to BioAlliance Pharma, covering the
specific method of administration of the gene coding for AMEP®
protein until 2026.
« We are particularly proud of these American grants as
patents based on the use of genes are particularly difficult to
obtain from the USTPO. These decisions reinforce and extend the
protection of our product and confirm the innovation brought by our
AMEP® biotherapy,” declares Aude Michel, Vice President Licensing
and Legal Affairs, and European Patent Attorney of BioAlliance
Pharma.
BioAlliance Pharma is pursuing the development of AMEP® with a
second European Phase I/II trial via intramuscular administration.
It aims at evaluating the safety and efficacy profile via systemic
route in patients with metastatic melanoma.
« Intellectual property is a key asset of the Company.
BioAlliance Pharma’s portfolio reflects the Company’s strategy and
its capacity of innovation; the portfolio today consists of 22
families of published patents, including 289 patents and patent
applications related to our products and technologies. The patents
granted by the American authorities on the AMEP® biotherapy
reinforce the value of this promising asset by ensuring a
protection on this key market, and ensure a protection already well
established,” added Judith Greciet, CEO of BioAlliance Pharma.
About BioAlliance Pharma
Dedicated to cancer and supportive care treatment with a focus
on resistance targeting and orphan products, BioAlliance conceives
and develops innovative products, for specialty markets especially
in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in
2005, BioAlliance Pharma’s ambition is to become a leading player
in these fields by coupling innovation to patient needs. The
company’s teams have the key competencies required to identify,
develop and register drugs in Europe and the USA.
BioAlliance Pharma has developed an advanced product
portfolio:
Specialty products
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised
patients): Registered in 28 countries (EU, US, Korea)
Sitavir®/Sitavig® (Acyclovir LauriadTM) (labialis herpes):
Positive phase III final results; registration status
Fentanyl LauriadTM (chronic cancer pain): Positive preliminary
Phase I results
Oncology Orphan products
Livatag® (Doxorubicin Transdrug™) (primary liver cancer): Phase
III on going
Validive® (Clonidine LauriadTM) (mucositis): Phase II on
going
AMEP® (invasive melanoma): Phase I on going
For more information, visit the BioAlliance Pharma web site at
www.bioalliancepharma.com
Disclaimer
This communication expressly or implicitly contains certain
forward-looking statements concerning BioAlliance Pharma SA and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors, which could cause the actual
results, financial condition, performance or achievements of
BioAlliance Pharma SA to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. BioAlliance Pharma SA is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.
For a discussion of risks and uncertainties which could cause
actual results, financial condition, performance or achievements of
BioAlliance Pharma SA to differ from those contained in the
forward-looking statements, please refer to the Risk Factors
("Facteurs de Risque") section of the 2011 Reference Document filed
with the AMF on April 24, 2012, which is available on the AMF
website (http://www.amf-france.org) or on BioAlliance Pharma SA's
website (http://www.bioalliancepharma.com).
Biotest (TG:BIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biotest (TG:BIO)
Historical Stock Chart
From Sep 2023 to Sep 2024